Anifrolumab (Saphnelo) listed in NS

March 6, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Nova Scotia effective March 1, 2024.

The public notice and listing criteria will appear on the Nova Scotia Pharmacare Programs website when the March Bulletin is posted.

Lupus Blog Articles:

Lupus and Heart Health: Understanding Cardiovascular Risk in SLE

Read

The Lupus Canada Annual General Meeting 2026

Read

Disability Benefits in Canada | Pathway to Benefits

Read